US Pharma MarketingDrug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. Semaglutide hits the GLP-1 receptor alone, tirzepatide adds a second in GIP, and next-generation candidates layer on a third in glucagon or drop incretins altogether for amylin and FGF21 biology. The competitive map is widening, too, as the Novo Nordisk and Eli Lilly duopoly meets oral small molecules, monthly dosing, and a wave of contenders from China. 2021 Semaglutide (Wegovy) is approved for obesity, kicking off the weight-loss era. 2022 Tirzepatide (Mounjaro) , a dual GIP/GLP-1 agonist, is approved for type 2 diabetes.…
The GLP-1 wave keeps widening Semaglutide hits the GLP-1 receptor alone, tirzepatide adds a second in GIP, and next-generation candidates layer on a third in glucagon or drop incretins altogether for amylin and FGF21 biology. The competitive map is widening, too, as the Novo Nordisk and Eli Lilly duopoly meets oral small molecules, monthly dosing,…
The post Diabetes to MASH: the specimens behind GLP-1’s widening roster appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development